Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients With Recurrent Solid Tumors
Citius Pharmaceuticals公司和Citius Oncology公司宣佈，Pembrolizumab（Keytruda®）和Lymphir™聯合用於複發性實體腫瘌癌症患者的研究者主導的I期臨床試驗取得了有希望的初步結果。
